related content
Webinar on public investment in medicines in Europe
The European Alliance for Responsible R&D and Affordable medicines organised in cooperation with Wemos, SOMO, Salud por Derecho, StopAids and Global Justice Now a webinar on public investments in biomedical research and development (R&D). The…
Overpriced drugs: SOMO and Wemos publication discussed in Dutch parliament
Recently, SOMO and Wemos published their research into the extent of Dutch public funding for drug development, through donations, loans and/or investments. The publication, Overpriced, reveals that because no conditions are set on these investments,…
Overpriced drugs developed with tax money
Research shows major Dutch public investment in drug development Overpriced, a report published today jointly by SOMO and Wemos examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This…
Overpriced
Drugs Developed with Dutch Public Funding
Position on supplementary protection certificates for medicinal products
In this joint statement, several civil society organisations have expressed their major concerns about the role of supplementary protection certificates (SPCs) in the accessibility and price of medicines in the Netherlands and elsewhere in Europe….
Common call to improve access to medicine
In the run-up to the general debate on Medicines policy on Thursday June 21st 2018, eight organizations in the Netherlands jointly sent a letter to the Dutch Parliament to inform them abouth their position concerning…
Organisations call for greater social impact of the European Commission’s medical research and innovation investments
Together with 22 civil society organisations, SOMO calls on the European Commission to seize the opportunity during the preparation of the 9th Framework Programme The 9th Framework Programme is the follow up of the Horizon…
Ethical verification of clinical trials on medication must be more stringent
Roche intimidates clinical drug trial participant following report
Following the publication of a critical report by SOMO on clinical drug trials in Egypt, pharmaceutical company Roche made reprehensible efforts to have damaging information removed from the report. They placed one of the interviewed…
Share this